Navigation Links
Valeant Announces Successful Results From Phase III Onychomycosis Trials
Date:12/16/2011

MISSISSAUGA, Ontario, Dec. 16, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced successful results from two large international Phase 3 studies of its topical investigational drug {efinaconazole (IDP-108)} product for the treatment of mild to moderate onychomycosis of the toenail. In both the studies, the investigational drug product was found to be statistically superior (p<0.001) to placebo for all primary and secondary endpoints. It was found to be generally safe and well tolerated.

Efinaconazole is an investigational antifungal drug belonging to the triazole family. The investigational drug product has not been found by the U.S. Food and Drug Administration (FDA) to be safe or effective for the treatment of mild to moderate onychomycosis of the toenail and may not be sold or promoted in the United States unless the FDA has approved a new drug application. Similar restrictions apply in other countries. 

Valeant holds an exclusive license from Kaken Pharmaceutical Co., Ltd., to commercialize efinaconazole in North America, Central America, South America and the European Union.

About Onychomycosis

Onychomycosis (also known as "dermatophytic onychomycosis" and "tinea unguium") is a fungal infection that affects the nail and nail bed. The prevalence of onychomycosis is about 6-8% in the adult population. It is the most common disease of the nail and constitutes about a half of all nail abnormalities. Without treatment, the nails thicken and cause localized pressure-related pain. Dermatophytes are the primary fungi that cause onychomycosis.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the successful approval and commercialization of IDP-108.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the successful approval and commercialization of IDP-108, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"). 

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
2. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
3. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
4. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
5. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
6. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
7. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
8. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
9. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
10. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
11. Valeant Pharmaceuticals to Present at Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- GenomeDx Biosciences today announced that six abstracts featuring Decipher ... Classifier tests will be presented at the 32 nd ... March 24 to 28, 2017 in London, ... Europe,s largest urological event showcasing the ... The abstract titled "Muscle invasive bladder cancer: ...
(Date:3/24/2017)... GENEVA , March 24, 2017 ... efforts to develop sutezolid as effective response to infectious ... TB Alliance and the Medicines Patent Pool (MPP) announced ... an antibiotic drug candidate which demonstrated encouraging results in ... sutezolid in combination with other TB drugs and follows ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Procedure By Technique, Repair Procedure By Technique, By Region, By Country ... ... to grow at a CAGR of 13.35% during 2016-2021 ... aging population, growth in population with heart disease and rising advances ...
Breaking Medicine Technology:
(Date:3/24/2017)... Maryland (PRWEB) , ... March 24, 2017 , ... ... is the first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I ... their caregivers during what is often a very difficult and challenging time.” , ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming of Christ, ... of published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation ... age ninety-one, he shares the Wisdom God bestowed upon him in this publication. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The ... about real people of God in congregations across the United States. “The ... minister ordained in 1964 who has served congregations in seven states throughout his ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health ... there could be four million Zika-related cases in the Americas within the next year. ... US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the opening ... at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the new ... in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an even ...
Breaking Medicine News(10 mins):